The North American business faced challenges, with revenue declining due to decreased Lenalidomide sales and increased price erosion for certain key products. Additionally, the delayed launch of biosimilars limited revenue growth during the quarter. However, Q3FY26 witnessed strong performance in India, Emerging markets, and the newly acquired consumer healthcare unit, which is focused on nicotine replacement therapy. The company aims to boost core business growth, advance patented products such as Semaglutide and Abatacept, improve operational...